EGFR and non-small cell lung carcinoma: The combination of amivantamab with a third‐generation EGFR‐TKI lazertinib in patients with osimertinib‐relapsed, chemotherapy‐naïve, EGFR‐mutated advanced NSCLC has shown preliminary efficacy, with an ORR of 36% and a median PFS of 4.9 months.264